RecruitingNot ApplicableNCT05772637
Clinical and Urodynamic Assessment of Bladder Sensation in Multiple Sclerosis
Sponsor
Assistance Publique - Hôpitaux de Paris
Enrollment
113 participants
Start Date
Feb 14, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
The aim of the study is to assess the association between bladder sensations progression during bladder filling and severity of Overactive bladder (OAB) in patients with multiple sclerosis.
Eligibility
Min Age: 18 YearsMax Age: 99 Years
Inclusion Criteria7
- Age ≥ 18
- MS according to the 2017 Mac Donald diagnostic criteria
- Bladder disorders supposedly related to MS
- Indication to perform urodynamics
- No current medication for bladder disorders
- Able to understand and right in French
- Affiliated to the "Securite sociale" or "Couverture Medicale Universelle (CMU)", or equivalent organism.
Exclusion Criteria8
- Legal protection
- Pregnancy or breastfeeding mother
- MS relapse during the past month
- Other associated neurological disease
- Genuine stress incontinence related to postpartum
- Treatment with antimuscarinics, alpha blockers, beta3 adrenergic, or tibial nerve stimulation in the past 15 days, or with botulinic toxin injection in the past 6 months
- Previous lower urinary tract surgery
- Inability to use the analogic device due to motor, sensory or ataxic disabilities
Interventions
PROCEDURERepeated cystometries with bladder sensations assessment
A second cystometry will be performed to assess bladder sensations reliability. A third cystometry with cognitive task (STROOP test) at the same time will be performed to assess the impact of distractive attentional task on bladder sensations
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05772637
Related Trials
Sacral Neuromodulation for Male Overactive Bladder (MOAB)
NCT0651114119 locations
Sexual Dysfunction in Women With Multiple Sclerosis (MS)
NCT071938231 location
Neuromodulating Cortical Regions Involved in Neurogenic Bladder in MS
NCT060727031 location
Safety and Efficacy of Botulinum Toxin A for Treatment of Overactive Bladder in Parkinson's Disease
NCT059970431 location
Lower Urinary Tract Symptoms After Intravesical Therapy
NCT058440591 location